130 related articles for article (PubMed ID: 33596143)
1.
Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
[No Abstract] [Full Text] [Related]
2. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
[TBL] [Abstract][Full Text] [Related]
3. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
5. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer.
Lu J; Dong W; He H; Han Z; Zhuo Y; Mo R; Liang Y; Zhu J; Li R; Qu H; Zhang L; Wang S; Ma R; Jia Z; Zhong W
Int J Biol Macromol; 2018 Oct; 118(Pt A):599-609. PubMed ID: 29874556
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
Cui F; Hu J; Ning S; Tan J; Tang H
Prostate; 2018 Dec; 78(16):1299-1310. PubMed ID: 30095171
[TBL] [Abstract][Full Text] [Related]
7. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
9. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
10. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.
Jia Y; Cheng X; Liang W; Lin S; Li P; Yan Z; Zhang M; Ma W; Hu C; Wang B; Liu Z
Curr Res Transl Med; 2022 Sep; 70(4):103345. PubMed ID: 35487167
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
12. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
13. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.
Huang Y; Jiang G; Liang X; Lan Z; Su Z; Wu H; Weng J; Jiang X
Mol Med Rep; 2018 Oct; 18(4):3914-3922. PubMed ID: 30132530
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
18. The Interaction between CLSPN Gene Polymorphisms and Alcohol Consumption Contributes to Oral Cancer Progression.
Hsieh MJ; Lo YS; Ho HY; Lin CC; Chuang YC; Chen MK
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256171
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]